RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) --  RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial  evaluating the biodistribution...

RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212 Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...

AREVA Med Inaugurates Second Lead-212 Production Facility PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic...

AREVA Med Partners With Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France) PLANO, Texas, Feb. 29, 2016 (GLOBE NEWSWIRE) -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute...